197 related articles for article (PubMed ID: 25431767)
1. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
[TBL] [Abstract][Full Text] [Related]
2. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
3. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
5. Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.
Braicu EI; Van Gorp T; Nassir M; Richter R; Chekerov R; Gasimli K; Timmerman D; Vergote I; Sehouli J
J Ovarian Res; 2014; 7():49. PubMed ID: 24872845
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
7. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
9. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
10. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
11. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
14. The value of frozen section evaluation in the management of borderline ovarian tumors.
Gultekin E; Gultekin OE; Cingillioglu B; Sayhan S; Sanci M; Yildirim Y
J Cancer Res Ther; 2011; 7(4):416-20. PubMed ID: 22269402
[TBL] [Abstract][Full Text] [Related]
15. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
Winarto H; Laihad BJ; Nuranna L
Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
[TBL] [Abstract][Full Text] [Related]
16. HE4 can help discriminate women with malignant ovarian
tumors only if CA125 levels are elevated.
Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
[TBL] [Abstract][Full Text] [Related]
17. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
18. Frozen section in borderline ovarian tumors: is it reliable?
Ureyen I; Turan T; Cirik DA; Tasci T; Boran N; Bulbul D; Tulunay G
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():115-8. PubMed ID: 25145763
[TBL] [Abstract][Full Text] [Related]
19. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
